Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Updated the “related topics”/glossary area to reflect the sponsor name branding (“Ono Pharmaceutical Co., Ltd.”) and added the associated “Revision: v3.5.3” site version marker, replacing the previous “Revision: v3.5.0” and slightly different formatting.
    Difference
    0.1%
    Check dated 2026-04-26T15:42:56.000Z thumbnail image
  2. Check
    18 days ago
    Change Detected
    Summary
    The term 'Melanoma' and the MedlinePlus Genetics related topic reference are removed from the page, diminishing visibility of the study's focus and its related resources.
    Difference
    0.1%
    Check dated 2026-04-12T11:48:32.000Z thumbnail image
  3. Check
    25 days ago
    Change Detected
    Summary
    Location entry updated from Padua, Italy to Padova, Italy to reflect local naming.
    Difference
    0.0%
    Check dated 2026-04-05T07:36:28.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    Added Melanoma as a related topic and MedlinePlus Genetics as a related topic. These additions enhance discoverability and contextual navigation without altering the core study details.
    Difference
    0.1%
    Check dated 2026-03-29T05:27:00.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Napoli, Italy, 80131 was updated to Naples, Italy, 80131, and the page revision was updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-21T23:59:22.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added; references to Melanoma, MedlinePlus Genetics, and Revision: v3.4.2 were removed. These appear to be administrative updates that do not change the study details or user interactions on the page.
    Difference
    0.1%
    Check dated 2026-03-07T14:52:53.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.